孟旭丽

◆导师基本情况

1.临床医学硕士，主任医师/党委副书记/副院长，硕士生导师

2.邮箱：mxlmail@126.com

3.指导专业：外科学 肿瘤学

◆研究领域

乳腺癌发生发展的机制研究

乳腺癌新辅助化疗增效减毒的中西医结合临床与机制研究

乳腺癌相关淋巴水肿的临床与机制研究

◆主讲课程

外科学研究进展

◆教育和工作经历

1.教育经历：

1985.09-1990.06    温州医学院    临床医学   本科

2002.11-2004.11    浙江大学医学院  临床医学  硕士

1999.11-2000.02  澳大利亚布里斯班皇家医院  乳腺外科  访学

2014.08-2014.09      美国MDAnderson乳腺外科 访学

2.工作经历：

1990.08-1996.11   浙江省肿瘤医院  头颈乳腺外科 住院医师

1996.12-2002.11   浙江省肿瘤医院  头颈乳腺外科 主治医师

2002.12-2007.11   浙江省肿瘤医院   乳腺外科 副主任医师

2007.12-2012.10   浙江省肿瘤医院   乳腺外科 主任医师/科教科科长2012.11-2014.09    浙江省肿瘤医院   乳腺外科 主任医师/门诊部主任/病区主任

2014.10-2019.10    浙江省立同德医院  乳腺甲状腺外科 主任医师/党委副书记/纪委书记

2019.11-2020.08浙江省人民医院  乳腺外科 主任医师/党委委员/纪委书记

2020.09-2022.07浙江省人民医院  乳腺外科 主任医师/党委委员/副院长

2020.09-2022.08浙江省人民医院  乳腺外科 主任医师/党委委员/副院长

2022.09-至今 浙江省人民医院  乳腺外科 主任医师/党委副书记/副院长

◆学术任职

1.中华中医药学会乳腺病专委会 副主委

2.中国抗癌协会乳腺癌专业委员会 委员

3.浙江省中西医结合学会乳腺病专业委员会 主任委员

4.浙江省抗癌协会乳腺癌专业委员会 副主任委员

◆主持教学科研项目

1.国家自然科学基金面上项目：Stathmin介导西黄丸调控肿瘤血管正常化及EMT在增强乳腺癌化疗疗效中的作用机制研究

2.省部共建项目：乳腺癌OTUD1表达水平与化疗疗效和预后的相关性分析及治疗方法研究

3.浙江省科技厅“尖兵”“领雁”研发攻关计划立项：智慧中医环境下西黄丸在乳腺癌新辅助化疗中应用的新技术研究及推广

4.国家中管局局省共建重点实验室-“上肢水肿瘀症诊治重点实验室”

5.浙江省卫生“领军人才”项目

◆代表性论著

主编《外周淋巴水肿：预防与治疗》

发表论文：

1. The breast cancer stem cells traits and drug resistance. Front Pharmacol. 2021 Jan 28;11:599965.

2. Naringenin regulates FKBP4/NR3C1/NRF2 axis in autophagy and proliferation of breast cancer and differentiation and maturation of dendritic cell. Front Immunol. 2022 Jan 11;12:745111.

3. Hyperglycemia and chemoresistance in breast cancer: from cellular mechanisms to treatment response. Front Oncol. 2021 Feb 25;11:628359. 

4. Integrated analysis of ceRNA network reveals prognostic and metastasis associated biomarkers in breast cancer. Front Oncol. 2021 May 13;11:670138. 

5. Necroptosis-Related LncRNAs signature and subtypes for predicting prognosis and revealing the immune microenvironment in breast cancer. Front Oncol. 2022 May 24;12:887318. 

6. Identification of ferroptosis-related prognostic signature and subtypes related to the immune microenvironment for breast cancer patients receiving neoadjuvant chemotherapy. Front Immunol. 2022 May 4;13:895110. 

7. LncRNA AWPPH as a prognostic predictor in human cancers in Chinese population: evidence from meta-analysis. Biosci Rep. 2021 Jun 25;41(6):BSR20210012. 

8. Identification of an lncRNA miRNA mRNA interaction mechanism in breast cancer based on bioinformatic analysis. Mol Med Rep. 2017 Oct;16(4):5113-5120. 

9. RNA sequencing uncovers molecular mechanisms underlying pathological complete response to chemotherapy in patients with operable breast cancer. Med Sci Monit. 2017 Sep 7;23:4321-4327. 

10. Establishment and characterization of novel human primary endometrial cancer cell line (ZJB-ENC1) and its genomic characteristic. J Cancer. 2019 Oct 20;10(25):6466-6474. 

11. Digital gene expression profiling analysis and its application in the identification of genes associated with improved response to neoadjuvant chemotherapy in breast cancer. World J Surg Oncol. 2018 Apr 23;16(1):82.

12. Role of CA19-9 in the prognostic evaluation of SOX neoadjuvant chemotherapy for   

gastric cancer. Int J Clin Exp Pathol. 2018 Nov 1;11(11):5387-5393.

13. Z-Guggulsterone Induces Cell Cycle Arrest and Apoptosis by Targeting the p53/CCNB1/PLK1 Pathway in Triple-Negative Breast Cancer. ACS Omega. 2023 Jan 3;8(2):2780-2792.

14. Substrate topography regulates extracellular matrix component secretion by bone marrow-derived mesenchymal stem cells. Journal of Science: Advanced Materials and Devices. 2022 Feb 21;7(2): 100437.

15. USP8 promotes cancer progression and extracellular vesicle-mediated CD8+ T cell exhaustion by deubiquitinating the TGF-β receptor TβRII. EMBO J. 2022 Jul 11:e108791.

16. The crosstalk between hippo-yap pathway and innate immunity. Front Immunol. 2020  Feb 27;11:323.

17. The IRENA lncRNA converts chemotherapy-polarized tumor-suppressing macrophages to tumor-promoting phenotypes in breast cancer. Nat Cancer. 2021 Apr;2(4):457-473.

18 .Nodular fasciitis of the breast: Report of two cases illustrating the diagnostic implications for USP6 gene rearrangement and brief review of the literature. Exp Mol Pathol. 2021 Dec;123:104690.

19. Construction and validation of prognostic nomogram for metaplastic breast cancer. Bosn J Basic Med Sci. 2022 Feb 1;22(1):131-139.

20 LncRNA POU3F3 promotes proliferation and inhibits apoptosis of cancer cells in triple-negative breast cancer by inactivating caspase 9. BiosciBiotechnolBiochem. 2019 Jun;83(6):1117-1123.

21. Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer. Amino Acids. 2016 Feb;48(2):487-97.

22. Engineered red blood cell membrane-coating salidroside/indocyanine green nanovesicles for high-efficiency hypoxic targeting phototherapy of triple-negative breast cancer. Adv Healthc Mater. 2022 Jun 23:e2200962.

23.Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer. Front Immunol. 2023 Jun 23;14:1153990.

24. 健脾疏肝饮对乳腺癌裸鼠移植瘤组织血管的影响[J]. 中华中医药杂志, 2021, 36(5):5.

25. 健脾疏肝饮降低乳腺癌剂量密集型化疗方案不良反应的临床研究[J]. 中华中医药杂志, 2020, 35(4):4.

◆成果奖励

“2022年卫生领军人才”

◆ 授权专利及转化  

1.实用新型专利：一种以气囊压缩程度来间接衡量淋巴水肿的装置